Doyle James Edward 4
4 · EXACT SCIENCES CORP · Filed Mar 23, 2026
Research Summary
AI-generated summary of this filing
Exact Sciences (EXAS) Director James Doyle Sells Shares in Merger
What Happened
James Edward Doyle, a director of Exact Sciences Corporation, had a total of 57,962 shares disposed on March 23, 2026 in connection with the company's merger with Abbott Laboratories. Under the merger agreement, each share of EXAS common stock was converted into $105.00 in cash, so the two dispositions (52,564 and 5,398 shares) produced aggregate cash consideration of $6,086,010. These dispositions are recorded as “Disposition to the issuer” (D) rather than open-market sales.
Key Details
- Transaction date: March 23, 2026. Price per share (merger consideration): $105.00.
- Shares disposed: 52,564 shares and 5,398 shares (total 57,962). Total proceeds: $6,086,010.
- Post-transaction common shares: The filing indicates outstanding common stock was converted into the merger cash consideration; common shares were cancelled at the Effective Time (so remaining public common shares would be eliminated).
- Footnotes: (F1) Merger with Abbott converted each outstanding share into $105 cash; (F2) restricted/vested shares granted under issuer plans were deemed fully vested and converted into the same cash consideration, net of applicable tax withholding.
- Filing timeliness: No late filing flag shown in the provided data.
Context
This disposition reflects the corporate action (merger) rather than an insider-initiated open-market sale; such conversion-type dispositions are routine in deal closings. Restricted shares that were outstanding prior to the Effective Time were treated as vested and converted into cash per the merger terms, subject to tax withholding.
Insider Transaction Report
- Disposition to Issuer
Common Stock
[F1]2026-03-23−52,564→ 5,398 total - Disposition to Issuer
Common Stock
[F2]2026-03-23−5,398→ 0 total
Footnotes (2)
- [F1]On March 23, 2026, pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of November 19, 2025, by and among Exact Sciences Corporation, a Delaware corporation (the "Issuer"), Abbott Laboratories, an Illinois corporation ("Parent"), and Badger Merger Sub I, Inc., a Delaware corporation and a direct, wholly owned subsidiary of Parent ("Merger Sub"), Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a direct, wholly owned subsidiary of Parent. At the effective time of the Merger (the "Effective Time"), on the terms and subject to the conditions set forth in the Merger Agreement, each share of the Issuer's common stock, par value $0.01 per share ("Common Stock"), issued and outstanding immediately prior to the Effective Time, with certain exceptions, was converted into the right to receive $105.00 in cash, without interest (the "Merger Consideration").
- [F2]At the Effective Time, each share of Common Stock subject to vesting, repurchase or other lapse restriction and that was granted under an Issuer stock plan and outstanding as of immediately prior to the Effective Time was deemed to be fully vested and cancelled and converted into the right to receive the Merger Consideration, less any applicable tax withholding.